Samsung Expands Its Reach: Acquisition of Infant Ultrasound AI Software Developer

Samsung has made a significant move in the healthcare technology sector by acquiring Sonio SAS, a French startup that specializes in AI-driven ultrasound software. Founded in 2020, Sonio focuses on enhancing the quality of care for women and infants through innovative artificial intelligence applications. According to the Centers for Disease Control and Prevention, one in every 33 babies born in the U.S. faces birth defects, underscoring the vital importance of early detection and monitoring during pregnancy.

Sonio’s advanced AI software aids healthcare professionals in conducting ultrasounds, facilitating the quick identification of key prenatal brain and heart structures. This technology streamlines workflows for healthcare workers, enabling them to provide expectant mothers with timely diagnoses and insights. The platform compiles findings into annotated images that can be easily shared with other medical professionals or the mothers themselves through a convenient QR code system.

Following the acquisition, Sonio will maintain its operations independently from Samsung Medison, ensuring that its software remains compatible with non-Samsung ultrasound devices—an important feature for widespread usability. “We greatly respect and admire what the Sonio team has accomplished in the field of maternal care,” commented Yong Kwan Kim, CEO of Samsung Medison. “With Sonio’s integration, we reinforce our commitment to enhancing the quality of life through technology.”

The collaboration between Samsung Medison and Sonio promises to merge top-tier ultrasound AI technology with robust reporting capabilities, potentially revolutionizing the prenatal ultrasound exam. Sonio has successfully raised $30 million to date, with support from investors like Elaia Partners, Cross Border Impact Ventures, and the European Innovation Council’s Fund. Notably, Sonio's AI solutions obtained 510(k) clearance from the U.S. Food and Drug Administration last August, affirming their safety and efficacy for clinical applications.

Now that Sonio has entered the U.S. market, its software solutions are also reaching international audiences through partnerships in India, Brazil, and Nigeria. “The combination of Samsung Medison’s established global ultrasound business and Sonio’s pioneering AI technology presents exciting growth potential for both entities,” said Cécile Brosset, CEO of Sonio. “We have found a trustworthy partner in Samsung Medison to accelerate our mission. As an independent company, we will continue to enhance medical reporting technology and diagnostic software on a global scale, particularly focusing on underserved healthcare areas.”